After launching a hunt for…
After launching a hunt for strategic alternatives in January following [...]
After a series of staff…
After a series of staff consolidation moves in recent weeks, [...]
Alumis is exploring strategic…
Alumis is exploring strategic alternatives for its would-be rival to [...]
Aardvark Therapeutics is planning…
Aardvark Therapeutics is planning to unblind data from its phase [...]
“Outliers are what you’re going…
“Outliers are what you’re going for,” Model Medicines CEO Daniel [...]
Andrea Pfeifer, Ph.D., the…
Andrea Pfeifer, Ph.D., the longtime leader of Swiss neurodegeneration outfit [...]
As the wave of in vivo CAR-T hype…
As the wave of in vivo CAR-T hype crests, Create [...]
A phase 2 trial of Biogen and…
A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting [...]
Regenxbio’s gene therapy for…
Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the [...]
Aptose Biosciences has scrapped a…
Aptose Biosciences has scrapped a deal for a blood cancer [...]